Medulloblastoma clinical trials
32 active trials name this condition. Describe your situation to see which ones look like a fit.
Refine by biomarker
By location
- Digoxin Medulloblastoma Study
- Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
- Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
- DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)
- A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
- PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
- Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
- HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
- PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
- Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
- Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
- Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
- GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
- PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
- A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
- C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
- 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
- CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation
- Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
- Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
- A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
- Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
- Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
- Asciminib With or Without Sildenafil for Brain Tumors
- B7-H3.CD28Z.CART in CNS Neoplasms
- my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
- Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Medulloblastoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.